Last reviewed · How we verify
CC-95266
At a glance
| Generic name | CC-95266 |
|---|---|
| Sponsor | Juno Therapeutics, a Subsidiary of Celgene |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE1)
- Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
- A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CC-95266 CI brief — competitive landscape report
- CC-95266 updates RSS · CI watch RSS
- Juno Therapeutics, a Subsidiary of Celgene portfolio CI